INSTANT STREAMING COURSE
Share:

Preapproval Inspection and Submission to the FDA

This course equips professionals to strengthen FDA inspection readiness, reduce submission-related compliance exposure, and improve operational coordination across manufacturing, documentation, validation, and facility controls. It supports more consistent regulatory execution for NDA, ANDA, and PMA submissions. This Course is designed for professionals responsible for regulated product manufacturing, submission readiness, quality systems, and compliance oversight.

REGISTER FOR THE COURSE

US $190 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $190 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    John E. Lincoln
  • Duration
    90 Minutes
  • Course ID
    TF1657
  • Ask the Expert
    Included
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

About the Course

Preapproval inspections conducted by the U.S. Food and Drug Administration directly influence whether NDA, ANDA, and PMA applications progress toward approval or face delays, observations, or rejection. Manufacturing controls, testing practices, documentation accuracy, validation status, and facility conditions are closely reviewed to determine whether products are consistently produced in accordance with current Good Manufacturing Practices and applicable regulatory requirements. Weak inspection preparation frequently exposes gaps in quality systems, establishment records, and process controls that can affect approval timelines and post-submission actions.


This webinar addresses the operational and regulatory expectations associated with FDA preapproval inspections for pharmaceutical and medical device products. Particular attention is given to inspection focus areas under 21 CFR 210/211 and 21 CFR 820, including personnel practices, equipment readiness, establishment file reviews, process validation, and handling FDA inquiries. The course also examines inspection risk factors, material rejection concerns, pharmacovigilance considerations, and documentation practices supporting submission credibility.

  • Strengthen Inspection Readiness and Submission Control:

    Participants will gain practical direction for preparing facilities, personnel, documentation, and validation activities for FDA preapproval inspections tied to NDA, ANDA, and PMA submissions. The course clarifies how inspection findings can affect approval progress and provides methods for identifying operational weaknesses before regulatory review activities expose compliance gaps or incomplete establishment records.

  • Improve Compliance Oversight Across Manufacturing Operations:

    The course provides focused insight into maintaining alignment between manufacturing practices, testing procedures, facility controls, and regulatory documentation under applicable FDA requirements. Participants will better understand inspection priorities associated with cGMP adherence, post-market considerations, and material rejection risks, helping organizations respond more effectively to regulatory scrutiny and submission-related inquiries.

Key Areas Covered

  • FDA preapproval inspection expectations for NDA, ANDA, and PMA submissions
  • cGMP compliance requirements under 21 CFR 210/211 and 21 CFR 820
  • Inspection focus areas involving personnel, facilities, equipment, validation, and documentation controls
  • Facility, product, and process risk assessment approaches supporting inspection preparation
  • Managing FDA inquiries, material rejection concerns, and post-market surveillance considerations
  • Pharmacovigilance responsibilities connected to product safety and regulatory approval activities
  • Establishment file review preparation and on-site inspection readiness practices
  • Documentation and recordkeeping methods supporting consistent submission and compliance performance

Who Must Attend

  • QA/QC Departments
  • Business Development Teams
  • Research and Development Teams
  • Regulatory Affairs Departments
  • Compliance Professionals
  • Validation Departments

Quality training, expert insights, and answers that matter. Know your Expert

JOHN E. LINCOLN

John E. Lincoln is Principal of J. E. Lincoln and Associates LLC and has more than 36 years of experience in FDA-regulated industries, including 22 years as an independent consultant. His work includes quality assurance, regulatory affairs, FDA responses, CAPA systems, validation activities, risk management files, and QMS remediation for pharmaceutical and medical device companies. He has conducted global workshops and webinars on FDA audits, GMP compliance, validation, root cause analysis, and regulatory submission-related quality requirements.

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How can a facility justify manufacturing changes made after submission but before a preapproval inspection?

Changes made after submission receive careful scrutiny because inspectors want assurance that the application still reflects the commercial manufacturing process. A change is easier to defend when the supporting rationale, risk assessment, and implementation records are complete before the inspection begins.


Change control documentation should explain why the modification was necessary, what product quality risks were evaluated, and whether additional validation or regulatory reporting was required. Technical conclusions should be supported by objective data rather than assumptions.


Inspectors frequently compare batch records, validation reports, procedures, equipment documentation, and quality records to determine whether the change was consistently implemented. Conflicting documentation often generates more concern than the change itself.


A defensible change demonstrates continuity. The supporting records should show that product quality, process performance, and regulatory commitments remained under control throughout implementation, leaving little room for uncertainty during inspection.

Why do FDA inspectors spend considerable time reviewing historical deviations during a preapproval inspection?

Historical deviations provide insight into how quality decisions are made when unexpected events occur. Inspectors review investigation records to determine whether problems were understood, corrected, and prevented from recurring through an effective quality system.


Repeated deviations involving the same equipment, manufacturing step, analytical method, or environmental condition often receive additional attention. Similar investigations with repeated conclusions can indicate that underlying process weaknesses remain unresolved.


The supporting evidence behind each investigation carries significant weight. Root cause analyses should align with production data, laboratory findings, maintenance records, and documented technical evaluations instead of relying on speculation.


Inspection confidence increases when historical records demonstrate consistent investigation practices and measurable corrective actions. Well documented improvements are more persuasive than repeatedly closing deviations without showing sustained operational control.

Which documentation weaknesses are most difficult to defend during a preapproval inspection?

Documentation becomes difficult to defend when records describing the same activity are inconsistent or incomplete. Inspectors compare procedures, batch records, validation reports, laboratory documentation, and electronic records to verify that they accurately reflect routine operations.


Technical decisions should be traceable throughout the quality system. Changes to specifications, process parameters, sampling plans, or investigation conclusions should include documented scientific justification that can withstand detailed review.


Timing also influences credibility. Records completed well after manufacturing activities, unexplained corrections, missing approvals, or conflicting revision histories can raise questions about data reliability and document control practices.


Documentation should provide a complete and consistent account of what occurred and why decisions were made. Records created during normal operations and supported by objective evidence are considerably easier to defend than explanations reconstructed during an inspection.

How do FDA inspectors distinguish between isolated quality issues and evidence of a weak quality system?

Inspectors rarely judge a quality system based on a single deviation or isolated inspection observation. Their assessment focuses on whether similar issues appear repeatedly across manufacturing, laboratory, engineering, validation, and quality records.


Patterns often reveal more than individual events. Recurring equipment failures, repeated investigation extensions, similar CAPA findings, or ongoing documentation deficiencies suggest that systemic controls are not functioning effectively despite individual corrective actions.


Inspectors also evaluate management responses to emerging trends. Quality metrics, internal audit findings, management review records, and effectiveness checks help demonstrate whether recurring issues were recognized, investigated, and resolved before they affected product quality.


A strong quality system consistently identifies, evaluates, and eliminates recurring risks through documented action. When evidence shows sustained improvement instead of repeated short term fixes, inspectors are more likely to view isolated issues as exceptions rather than indicators of broader system weakness.

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can watch the course, access materials, and manage your learning.

3. Access course materials
The presentation handout and other materials can be downloaded inside the Course Player. You could use Discussion feature there to ask your questions.

4. Watch The Streaming and Complete your Course
The course playback will be available on the same course page. You could pause and continue or you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

The challenge with training is rarely signing up. It’s what happens afterward, when access, materials, & certification aren’t accessible from one place.
With TalkFDA Courses, Everything you need Live in One Place.
Simple. Organized. Professional.
Go ahead and Take the Course with confidence.

Our students love us ❤️

“Good breakdown of what FDA inspectors usually focus on during preapproval reviews. Helped connect documentation practices with actual inspection expectations.”

Manager, QA

“Some good points came up during Q&A. That part was useful for us.”



Auditor, Compliance

“Helpful session on how documentation issues can affect submission timelines and approvals. Gave better visibility into the compliance side of product planning.”

Manager, Business Development

People who took this Course, also viewed